Cargando…
Efficacy and safety of S‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis
BACKGROUND: S‐1 monotherapy is effective and feasible for previously treated patients with advanced non‐small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to eval...
Autores principales: | Imai, Hisao, Minemura, Hiroyuki, Kishikawa, Takayuki, Yamada, Yutaka, Suzuki, Kensuke, Umeda, Yukihiro, Wasamoto, Satoshi, Kasahara, Norimitsu, Ishihara, Shinichi, Yamaguchi, Ou, Naruse, Ichiro, Uchino, Junji, Mori, Keita, Kanazawa, Kenya, Shibata, Yoko, Kasai, Takashi, Kaburagi, Takayuki, Kaira, Kyoichi, Minato, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529563/ https://www.ncbi.nlm.nih.gov/pubmed/32844570 http://dx.doi.org/10.1111/1759-7714.13622 |
Ejemplares similares
-
A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
por: Imai, Hisao, et al.
Publicado: (2017) -
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis
por: Imai, Hisao, et al.
Publicado: (2018) -
Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021) -
Post‐progression survival after atezolizumab plus carboplatin and etoposide as first‐line chemotherapy in small cell lung cancer has a significant impact on overall survival
por: Masubuchi, Ken, et al.
Publicado: (2022) -
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021)